2025 Hematology Highlights: A Post-ASH Review (Attendee Information)

In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

The University of Nebraska Medical Center designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

The University of Nebraska Medical Center designates this activity for 4.0 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Pharmacists

The University of Nebraska Medical Center designates this activity for 4.0 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. UAN # JA0000319-0000-25-002-L01-P

In order for pharmacists to claim credit for their participation in the conference, each individual must complete the online evaluation and ensure that their date of birth (mm/dd), as well as their NABP e-Profile ID # is on record with UNMC. Pharmacists have up to 20 days to complete the evaluation and claim credit for participation. UNMC will ensure that required registrant data is provided to CPE Monitor.

Read the UNMC CCE Disclosure Declaration Policy 

Disclosures

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

FACULTY

The following have disclosed relevant financial relationships:

• Vijaya Raj Bhatt, MBBS, MS*
  Advisory Board: Protagonist Therapeutics, Inc.
  Consultant: Imugene Limited; Sanofi; Taiho Oncology, Inc.
  Contracted Research: MEI Pharma, Inc.; National Marrow Donor Program; Sanofi
  Grant/Research Support: AbbVie, Inc.; Actinium Pharmaceuticals, Inc.; Incyte Corporation; Jazz Pharmaceuticals, Inc.; Pfizer, Inc.
  Other Financial or Material Support: Chimerix
• Prithviraj Bose, MD
  Consultant/Honoraria: AbbVie, Inc.; Blueprint Medicines Corporation; Bristol Meyers Squibb Company; Cogent Biosciences, Inc.; Disc Medicine; Geron; GlaxoSmithKline LLC; Incyte Corporation; Ionis Pharmaceuticals, Inc.; Jubilant Pharma Limited; Karyopharm; Keros Therapeutics; Morphic (Eli Lilly and Company); MorphoSys (Novartis Pharmaceuticals Corporation); Novartis Pharmaceuticals Corporation; Ono Pharma USA, Inc.; PharmaEssentia Corporation; Raythera; Sobi, Inc.; Sumimoto Pharma Co., Ltd.
  
  Contracted Research: Ajax Therapeutics; Blueprint Medicines Corporation; Bristol Meyers Squibb Company; Cogent Biosciences, Inc.; Disc Medicine; Geron; Incyte Corporation; Ionis Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Kartos Therapeutics, Inc.; Karyopharm; MorphoSys (Novartis Pharmaceuticals Corporation); Sobi, Inc.; Sumitomo Pharma Co., Ltd.; Telios Pharmaceuticals, Inc.
  
  INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE:
  Off-label drug discussion of bezuclastinib for systemic mastocytosis.
  Off-label drug discussion of CK0804, DISC-0974, elritercept, flonoltinib, imetelstat, INCB057643, luspatercept, navtemadlin, nuvisertib, and selinexor for myelofibrosis.
  
  
• Elizabeth A. Brém, MD
  Advisory Board: ADC Therapeutics; BeiGene USA, Inc.; Caribou Biosciences; Genentech, Inc.
  Consultant: Caribou Biosciences; Genentech, Inc.; Incyte Corporation; Regeneron
  Speaker’s Bureau: AbbVie, Inc.; AstraZeneca Pharmaceuticals; BeiGene USA, Inc.; Bristol Meyers Squibb Company; Genmab US Inc.
  Steering Committee: Regeneron
  
  INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE:
  Off-label drug discussion of venetoclax/acalabrutinib combo. Will discuss recently presented combination data.
  
  
• Christopher R. D’Angelo, MD*
  Advisory Board: AbbVie, Inc.; Bristol Meyers Squibb Company; Curis, Inc.; Ono Pharma USA, Inc.; Pfizer/Seagen
  Consultant: AbbVie, Inc.
  Grant/Research Support: AbbVie, Inc.; BeiGene USA, Inc.; Bristol Meyers Squibb Company; Curis, Inc.; Fate Therapeutics; Ono Pharma USA, Inc.
  
  
• Yasmin H. Karimi, MD
  Advisory board: AbbVie, Inc.; ADC Therapeutics; AstraZeneca Pharmaceuticals; Genmab US, Inc.
  Consultant: AbbVie, Inc.; Genentech, Inc.; Genmab US, Inc.; Merck & Co., Inc.
• Rami Komrokji, MD
  Advisory Board: AbbVie, Inc.; Bristol Meyers Squibb Company; Daiichi Sankyo, Inc.; Les Laboratoires Servier; PharmaEssentia Corporation; Rigel Pharmaceuticals, Inc.; Sobi, Inc.; Sumitomo Pharma Co., Ltd.
  Consultant: Genentech, Inc.; Geron; Sumitomo Pharma Co., Ltd.
  Research Grant: Bristol Meyers Squibb Company
  Speakers' Bureau: Les Laboratoires Servier; PharmaEssentia Corporation; Raythera; Rigel Pharmaceuticals, Inc.; Sobi, Inc.
• Selina M. Luger, MD, FRCPC
  Advisory Board: Amgen, Inc.; Daiichi Sankyo, Inc.
  Consultant: Amgen, Inc.
• Jared E. Matya, PharmD, BCOP*
  Advisory Board: Acerta Pharma/AstraZeneca Pharmaceuticals; SERB Pharmaceuticals (formerly BTG Pharmaceuticals)
  Honorarium Recipient: SERB Pharmaceuticals (formerly BTG Pharmaceuticals); Medscape
• Alex B.D. Nester, MD
  Advisory Board: Bayer
• Timothy M. Schmidt, MD
  Consultant: BioLineRX, Ltd.; Johnson & Johnson; Pfizer, Inc.; Sanofi
  Research Funding: Alexion Pharmaceuticals, Inc.; Bristol Meyers Squibb Company; Johnson & Johnson
  
  INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE:
  Off-label drug discussion of anitocabtagene autoleucel in early phase clinical trial data.
  Off-label drug discussion of daratumumab in smoldering myeloma trial data.
  Off-label drug discussion of teclistamab in early trial data from newly-diagnosed myeloma.
  
  
• Tanya M. Wildes, MD, MSCI
  Consultant: Janssen Pharmaceuticals, Inc.; Pfizer, Inc.

The following has nothing to disclose:

• Ashley Bogus, PharmD, BCOP

PLANNING COMMITTEE

The following have nothing to disclose:

• Valeta Creason-Wahl, MMP
• Tori Greenlee
• Heidi Keeler, PhD, MSN/MBA, RN
• Renee Paulin, MSN, RN, CWOCN
• Brenda Ram, CMP, CHCP
• Shannan Wilson, BS, RRT

*Faculty and planning committee member

The following materials (in PDF) are available for download until Feb. 21, 2025. No part of these materials may be reproduced without prior written permission.

• Acute Leukemia
  Selina M. Luger, MD, FRCPC
• Myeloproliferative Neoplasms
  Prithviraj Bose, MD
• Myelodysplastic Syndromes
  Rami Komrokji, MD
• Chronic Lymphocytic Leukemia
  Elizabeth A. Brém, MD
• Lymphoma
  Yasmin H. Karimi, MD
• Multiple Myeloma
  Timothy M. Schmidt, MD
• Bispecific Antibody (BsAb) Pharmacy
  Ashley Bogus, PharmD, BCOP
• Clotting Diseases
  Alex B.D. Nester, MD
• Geriatric Oncology
  Tanya M. Wildes, MD, MSCI